Transaction DateRecipientSharesTypePriceValue
22nd December 2020Management Inc. Opaleye15,900Open or private purchase$5.19$82,597.32
22nd December 2020Management Inc. Opaleye657Open or private purchase$5.19$3,412.98
22nd December 2020Management Inc. Opaleye496,277Open or private purchase$8.06$3,999,992.62
21st December 2020Management Inc. Opaleye51,400Open or private purchase$5.24$269,305.16
21st December 2020Management Inc. Opaleye2,059Open or private purchase$5.24$10,787.92
18th December 2020Management Inc. Opaleye1,400Open or private purchase$5.31$7,437.64
18th December 2020Management Inc. Opaleye35,000Open or private purchase$5.31$185,941.00
7th December 2020Richard L Md Lindstrom32,127Grant/award etc.$0.00
4th December 2020Charles M Warden745,597Other acquisition or disposition$0.00
4th December 2020Charles M Warden3,619Other acquisition or disposition$0.00
Ocular Therapeutix
Ocular Therapeutix logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Ocular Therapeutix, Inc. is a biopharmaceutical company. It engages in the development and commercialization of therapies for diseases and conditions of the eye. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi in 2006.

Ticker: OCUL
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1393434
Employees: 161
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $84 M (0%)
Inventory, Net: $1 M (0%)
Assets, Current: $90 M (50%)
Property, Plant and Equipment, Net: $9 M (-11%)
Assets: $107 M (36%)
Accounts Payable, Current: $3 M (-18%)
Accrued Liabilities, Current: $6 M (-24%)
Liabilities, Current: $14 M (14%)
Liabilities: $102 M (23%)
Common Stock, Value, Issued: $6 Th (20%)
Common Stock, Shares, Issued: $63 M (25%)
Additional Paid in Capital, Common Stock: $447 M (17%)
Retained Earnings (Accumulated Deficit): $442 M (0%)
Stockholders' Equity (Parent): $5 M (0%)
Liabilities and Equity: $107 M (36%)
Revenue: $2 M (0%)
Cost of Revenue: $134 Th (-85%)
Research and Development: $8 M (-43%)
Sales and Marketing: $6 M (-53%)
General and Administrative Expenses: $5 M (-50%)
Operating Income/Loss: $18 M (-48%)
Other Income, net: $19 M (-20%)